Latest Conference Articles

Cognitive behavioral therapy (CBT) can be used in conjunction with medication and community care to treat psychosis and incorporate families and caregivers into the treatment process, according to David Kingdon, MD, professor of mental health care delivery, University of Southampton.

Jason Mitchell, MD, chief medical and clinical transformation officer, Presbyterian Healthcare Services, discusses which payment models have the most potential for succeeding in value-based care.

Erich Mounce, chief operating officer, OneOncology, discusses how payment models like the Oncology Care Model are changing the way oncologists practice, as well as what practices should prioritize when looking to participate in a payment model.

Lori Raney, MD, principal, Health Management Associates, provided a definition and examples of integrated care for physical and behavioral health, in addition to explaining the strengths of the collaborative care model.

Selected technology news briefs from the 79th Scientific Sessions of the American Diabetes Association.

The final morning session of the 79th Scientific Sessions of the American Diabetes Association (ADA) in San Francisco, California, featured more cardiovascular and renal results from recent trials involving type 2 diabetes drugs.

Care coordination is crucial for mitigating challenges associated with aging and survivorship, explained Rose Gerber, director of patient advocacy and education for the Community Oncology Alliance.

Oral semaglutide, the first glucagon-like peptide 1 (GLP-1) receptor agonist in a pill, met safety benchmarks and reduced major cardiovascular (CV) events for high-risk patients with type 2 diabetes (T2D) in PIONEER 6, but did not achieve superiority, according to trial results presented at the 79th Scientific Sessions of the American Diabetes Association in San Francisco, California.

Adam Simmons, director of clinical program management, Alkermes, interviewed at the American Psychiatric Association Annual Meeting, discussed the efficacy of the investigational drug ALKS 3831 (olanzapine/samidorphan) in various patient populations.

One of the first things you need to do to ensure scalability and sustainability of social determinants of health (SDOH) initiatives is to really understand your population, explained Susan Mani, MD, vice president of Clinical Transformation and Ambulatory Quality at LifeBridge Health.

The observational study will use information from 3 databases to compare the SGLT2 inhibitor to a competing class of therapy for type 2 diabetes. Early cardiovascular and safety data were presented Monday at the 79th Scientific Sessions of the American Diabetes Association.

Findings reported at the 79th Scientific Session of the American Diabetes Association in San Francisco, California, show the type 2 diabetes drug dapagliflozin significantly reduced the risk of renal decline, kidney failure, and renal death.

Results from a study involving adding sitagliptin and increasing doses of metformin for patients who cannot attain glycemic control show that as glycated hemoglobin increases, it becomes harder to reach targets.

Oral semaglutide would be the first non-injectable agent in the GLP-1 receptor agonist class; these drugs produce powerful glycemic control along with weight loss.

This is probably the biggest concern that every community and cancer practice should be looking at, explained Ben Jones, vice president, Government Relations & Public Policy, McKesson Specialty Health.

One of the most important things you can do to align healthcare strategies in the shift toward value-based care is to allow your clinicians to be part of that journey, explained Jason Mitchell, MD, chief medical and clinical transformation officer, Presbyterian Healthcare Services.

Results of the CLL14 trial, which were presented today at the 2019 Annual Meeting of the American Society of Clinical Oncology in Chicago, Illinois, resulted in the approval of the venetoclax combination for these patients in May.

A number of abstracts at the 2019 American Society of Clinical Oncology Annual Meeting, held May 31 to June 4, 2019, in Chicago, Illinois, featured studies that focused on using real-world data to advance research and cancer care in non–small cell lung cancer (NSCLC).

During the American Society of Clinical Oncology’s Annual Meeting which took place May 31-June 4, 2019 in Chicago, Illinois, oncologists and representatives from UnitedHealthcare and the Center for Medicare and Medicaid Innovation (CMMI) took the stage to discuss oncology reimbursement reform and whether there are changes on the horizon for the promotion of higher value care.

The follow-up to the landmark TAILORx trial shows that adding a clinical risk evaluation of the breast cancer tumor may have prognostic value; the authors' recommendations are drawn from other studies.

Jonathan Campbell, PhD, associate professor, Department of Clinical Pharmacy, Pharmaceutical Outcomes Research, Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of Colorado, discusses the value of multi-criteria decision analysis (MCDA) in value assessment, as well as lessons learned from using MCDA in other industries.

Parth Shah, PharmD, PhD, of the Fred Hutchinson Cancer Research Center, led a discussion on the uptake challenges of the human papilloma virus (HPV) vaccine at the American Society of Clinical Oncology’s Annual Meeting by first explaining the known percentages of attributable cancers to the virus in the United States: cervical cancer 91%, vagina cancer 75%, and vulva cancer 69%, among others. Although multiple cancers are attributable to the virus, explained Shah, of the population ages 13-17 in the United States that should be vaccinated, both boys and girls, only 49% actually receive the vaccine.

Oncologists, patient advocates, patients, and other stakeholders from around the world gathered to hear different perspectives regarding the use of cannabis in symptom management for patients with cancer. Panelist after panelist went up to present available data, and each reiterated the same point: We need more research.

Group purchasing organizations have an important purpose in healthcare, but there are some concerns, explained Martin Makary, MD, MPH, a surgical oncologist and chief of the Johns Hopkins Islet Transplant Center.

Patients with advanced pancreatic cancer linked to germline genetic mutations did not see their disease worsen for an additional 3.6 months when treated with olaparib, but an early interim analysis did not show a statistically significant difference in overall survival (OS), according to study results presented Sunday at the American Society of Clinical Oncology Annual Meeting 2019.

Drug pricing seemed like an appropriate topic for ASCO's town hall as the Trump administration has made lowering the cost of medications a major objective. By doing so, the administration has put out a series of proposals looking to address the cost of drugs, such as the International Pricing Index (IPI), and the recently finalized rule around direct-to-consumer advertising for pharmaceutical companies.

Erich Mounce, chief operating officer, OneOncology, discusses the importance of palliative care and how it impacts quality of life.

“How do you currently collaborate with your primary care colleagues in caring for patients with cancer?” This was how Larissa Nekhlyudov, MD, MPH, opened a session titled “Bringing the Primary Care Physician Back Into Cancer Care,” during the American Society of Clinical Oncology’s Annual Meeting, held in Chicago, Illinois from May 31-June 4, 2019.